Aytu BioPharma signs exclusive deal with Medomie Pharma for ADHD drugs in Israel, Palestinian Authority

AYTU BIOPHARMA, INC

Exclusive collaboration, distribution and supply agreement for Adzenys XR-ODT and Cotempla XR-ODT in Israel and Palestinian Authority.
Medomie will seek local regulatory approvals and marketing authorizations; first international commercial agreement for these ADHD products.
Aytu CEO Josh Disbrow cites potential to improve patient compliance and reduce therapy misuse in underserved markets.
No financial terms disclosed; export to Medomie after regulatory approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.